Recent patents on cardiovascular stem cells

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 1, 2008, Pages 59-72

  Jakob, Marten ^a   Thum, Thomas ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Adult stem cells; Embryonic stem cells; Heart failure; Myocardial infarction; Patents; Regenerative medicine

Indexed keywords

ALKALOID; CD31 ANTIGEN; CD34 ANTIGEN; CD36 ANTIGEN; CD38 ANTIGEN; CHOLINESTERASE INHIBITOR; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; EPIBATIDINE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYALURONIC ACID; INDOMETACIN; LOBELINE; MICROSOMAL AMINOPEPTIDASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINE; NICOTINE RECEPTOR BLOCKING AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; RECEPTOR BLOCKING AGENT; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 1; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELL DIFFERENTIATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG MEGADOSE; EMBRYONIC STEM CELL; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NONHUMAN; PATENT; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TISSUE PERFUSION;

ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; PATENTS AS TOPIC; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 38949138507     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008783331634     Document Type: Review

References (162)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018.
2. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: Eighteen months' follow-up data from the randomized, Controlled BOOST (bone marrow transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113: 1287-1294.
3. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary Bone Marrow-Derived Progenitor Cells in Acute Myocardial Infarction. N Engl J Med 2006; 355: 1210-1221.
4. Bearzi C, Rota M, Hosoda T, et al. Human cardiac stem cells. PNAS 2007; 104: 14068-14073.
5. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotech 2007; 25: 1015-1024.
6. De Coppi P, Bartsch G, Siddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotech 2007, 25: 100-106.
7. Agbulut O, Vandervelde S, Al Attar N, et al. Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. J Am Coll Cardiol 2004; 44: 458-463.
8. Freyman, T.: US20060263341A1 (2006).
9. Freyman, T.: US20067097833 (2006).
10. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-705.
11. Hess DC, Hill WD, Martin-Studdard A, et al. Bone marrow as a source of endothelial cells and NeuN-expressing cells After stroke. Stroke 2002; 33: 1362-1368.
12. Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3: 1337-1345.
13. Asakura A, Rudnicki MA. Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. Exp Hematol 2002; 30: 1339-1345.
14. Asakura A, Seale P, Girgis-Gabardo A, Rudnicki MA. Myogenic specification of side population cells in skeletal muscle. J Cell Biol 2002; 159: 123-134.
15. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279-4295.
16. Katz AJ, Tholpady A, Tholpady SS, Shang H, Ogle RC. Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. Stem Cells 2005; 23: 412-423.
17. Fraser, J.K., Hedrick, M.H., Zhu, M., Strem, B.M., Daniels, E., Wulur, I.: US20060083720A1 (2006).
18. Strem, B.M.: MX5009044A (2006).
19. Franco, W.P.: US2007766280 (2007).
20. Edelberg, J., Rafii, S., Hong, M., Lanza, R.P., West, M.D.: US20077135171 (2007).
21. Hristov M, Erl W, Weber PC. Endothelial progenitor cells:. mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003; 23: 1185-1189.
22. Thum T, Hoeber S, Froese S, et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res 2007; 100: 434-443.
23. Edelberg JK Lee SH, Kaur M, et al. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart Circulation 2002; 105: 608-613.
24. Pilarsky, L.M.: US6875753 (1997).
25. Klypstra FB, Bottcher CJ, van Melsen JA, van der Laan EJ. Distribution and composition of acid mucopolysaccharides in normal and atherosclerotic human aortas. J Atheroscler Res 1967; 7: 301-309.
26. Tammi M, Seppala PO, Lehtone A, Mottonen M. Connective tissue components in normal and atherosclerotic human coronary arteries. Atherosclerosis 1978; 29: 191-194.
27. Fenderson BA, Stamenkovic I, Aruffo A. Localization of hyaluronan in mouse embryos during implantation, gastrulation and organogenesis. Dffereatiation 1993; 54: 85-98.
28. Weigel PH, Frost SJ, McGary CT, LeBoeuf RD. The role of hyaluronic acid in inflammation and wound healing. Int J Tissue React 1988; 10: 355-365.
29. Robertson NP, Starkey JR, Hamner S, Meadows GG. Tumor cell invasion of three-dimensional matrices of defined composition: evidence for a specific role for heparan sulfate in rodent cell lines. Cancer Res 1989; 49: 1816-1823.
30. Entwistle J, Hall CL, Turley EA. HA receptors: regulators of signalling to the cytoskeletor. J Cell Biochem 1996; 61: 569-577.
31. Bridger, G.J., Abrams, M.J., Henson, G.W., MacFarland, R.T., Calandra, G.B., Broxmeyer, H.E., et al.: US20066987192 (2006).
32. Bridger, G.J., Abrams, M.J., Henson, G.W., MacFarland, R.T., Calandra, G.B.: U820077169750 (2007).
33. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595-599.
34. Mohle R, Bautz F, Rafii S, et al. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998; 91: 4523-4530.
35. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005; 46: 1693-1701.
36. Thum T, Fraccarollo D, Schultheiss M, et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 2007; 56: 666-674.
37. Lutz, A., Eizenhofer, H., Zeiher, A.M., Dimmeler, S., Heeschen, C., Aicher, A.: US20060246044A1 (2006).
38. Nishida T, Shimokawa H, Oi K. et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation 2004; 110: 3055-3061.
39. Wang CJ, Wang FS, Yang KD, et al. Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rabbits. J Orthop Res 2003; 21: 984-989.
40. Gotte G, Amelio E, Russo S, et al. Short-time non-enzymatic nitric oxide synthesis from L-arginine and hydrogan peroxide induced by shock waves treitiment FEBS Lett 2002; 520: 153-155.
41. Aicher A, Heeschen C, Sasaki Ki, et al. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: A new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation 2006; 114: 2823-2830.
42. Soykan, O., Donovan. M.G.: US20067155288 (2006).
43. Duan C, Trumble DR, Scalise D, Magovern JA. Intermittent stimulation enhances function of conditioned muscle. Am J Physiol 1999; 276: R1534-R1540.
44. Mills WF, Mal N, Kiedrowski MJ, et al. Stem cell therapy enhances electrical viability in Myocardial infarction. J Mol Cell Cardiol 2007; 42: 304-314.
45. Carmeliet P. Mechanism of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
46. Colb, A.M., Gold, H.K.: US20077172758 (2007).
47. Castaneda-Zuniga WR, Formanek A, Tadavarthy M, et al. The mechanism of balloon angioplasty. Radiology 1980; 135: 565-571.
48. Kramsch DK Hollander W. The interaction of serum and arterial lipoproteins with elastin of the arterial intima and its role in the lipid accumulation in atherosclerotic plaques. J Clin Invest 1973; 52: 236-247.
49. Duber C, Jungbluth A, Rumpelt HJ, et al. Morphology of the coronary arteries after combined thrombolysis and percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1986; 58: 698-703.
50. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
51. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105: 71-77.
52. Thum T, Bauersachs J. Endothelial progenitor cells as potential drug targets. Curr Drug Targets Cordiovasc Haematol Disord 2005; 5:277-286.
53. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
54. Buchwald AB, Sandrock D, Unterberg C, et al. Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J Am Coll Cardiol 1993; 21: 249-254.
55. Reyes M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone Marrow. J Clin Invest 2002; 109: 337-346.
56. Gehling UM, Ergun S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; 95: 3106-3112.
57. Brugger W, Henschler R, Heimfeld S, et al. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoictic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994; 84: 1421-1426.
58. Quirici N, Soligo D, Caneva L, et al. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 2001; 115: 186-194.
59. Vas V, Hajdu M, Paloczi K, Uher F. Alternative views of tissue stem cell plasticity. Haematologia (Budap) 2002; 32: 175-190.
60. Shi Q, Rafii S, Wu MR, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362-3670
61. Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001; 103: 634-7.
62. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents costed with antibody against CD34: the HEALING-FIM (Healthy Endotholial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005; 45: 1574-1579.
63. Whitehouse, M.J.: US20067112560 (2006).
64. Maciag T, Mehiman T, Friesel R, Schreiber AB. Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science 1984; 225: 932-935.
65. Shing Y, Folkman J, Sullivan R, et al. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 1984; 223: 1296-1299.
66. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20: 563-569.
67. Bastaki M, Nelli EE, Dell'Era P, et al. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Arterioscler Thromb Vasc Biol 1997; 17: 454-464.
68. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002; 8: 483-489.
69. Ozaki H, Okamoto N, Ortega S, et al. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am J Pathol 1998; 153: 757-765.
70. Miller DL, Ortega S, Bashayan O, Basch R, Basilico C. Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol 2000; 20: 2260-2269.
71. Battler A, Scheinowitz K Bor A, et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993; 22: 2001-6.
72. Yanagisawa-Miwa A, Uchida Y, Nakamura F, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblas growth factor. Science 1992; 257: 1401-1413.
73. Unger EF, Banai S, Shou M, et al. A model to assess interventions to improve collateral blood flow: continuous administration of agents into the left coronary artery in dogs. Cardiovasc Res 1993; 27: 785-791.
74. Lazarous DF, Scheinowitz M, Shou M, et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995; 91: 145-153.
75. Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994; 94: 623-630.
76. Lopez JJ, Edelman ER, Stamler A, et al. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters. J Pharmacol Exp Ther 1997: 282: 385-390.
77. Laham RJ, Rezaee M, Port M, et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcinc model of chronic myocardial ischemia. J Pharmacol Exp Ther 2000; 292: 795-802.
78. Ruel M, Sellke FW. Angiogenic protein therapy. Semin Thorac Cardiovasc Surg 2003; 15: 222-235.
79. Wilson, E.L., Gabrilove, J.: US5817773 (1998).
80. Ratajczak MZ, Ratajczak J, Skorska M, et al. Effect of basic (FGF-2) and acidic (FGF-1) fibroblast growth factors on early haemopoietic cell development. Br J Haematol 1996; 93: 772-782.
81. Cavanagh JF, Mione MC, Pappas IS, Parnavelas JG. Basic fibroblast growth factor prolongs the proliferation of rat cortical progenitor cells in vitro without altering their cell cycle parameters. Cereb Cortex 1997; 7: 293-302.
82. Hossain WA, Morest DK. Fibroblast growth factors (FGF-1, FGF-2) promote migration and neurite growth of mouse cochlear ganglion cells in vitro: immunohistochemistry and antibody perturbation. J Neurosci Res 2000; 62: 40-55.
83. Freedman SB, Isner JM. Therapeutic angiogonesis for coronary artery disease. Ann Intern Med 2002; 136: 54-71.
84. Detillieux KA, Sheikh F, Kardami E, Cattini PA. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 2003; 57: 8-19.
85. Jiang ZS, Padua RR, Ju H, et al. Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 2002; 282: H1071-H1080.
86. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002; 105: 788-793.
87. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000; 113 (Pt 7): 1161-1166.
88. Martin I, Muraglia A, Campanile G, Cancedda R, Quarto R. Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow. Endocrinology 1997; 138: 4456-4462.
89. Bianchi G, Banfi. A, Mastrogiacomo M, et al. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res 2003; 287: 98-105.
90. Stegman, T.J.: US20077252818 (2007).
91. Thompson JA, Anderson KD, DiPietro JM, et al., Site-directed neovessel formation in vivo. Science, 1988; 241: 1349-52.
92. Dionne CA, Crumley G, Bellot F, et al. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors, EMBO J 1990; 9: 2685-2692.
93. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97: 645-650.
94. Fernandez B, Buehler A, Wolfram S, et al. Transgenic myocardial overexpression of fibroblast growth factor-1 increases coronary artery density and branching. Circ Res 2000; 87: 207-213.
95. Cooke, J., Jang, J., Tsao, P., Heeschen, C.: US20077160904 (2007).
96. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001; 7: 833-839.
97. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382: 255-257.
98. Macklin KD, Maus AD, Pereira EF, Albuquerque EX, Conti-Fine BM. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1998; 287: 435-439.
99. Grando SA, Horton RM, Pereira EF, et al. A nicotinic acetyl-choline receptor regulating cell adhesion and motility is expressed inhuman keratinocytes. J Invest Dermatol 1995; 105: 774-781.
100. Wessler I, Kirkpatrick CJ, Racke K. The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems including humans. Clin Exp Pharmacol Physiol 1999; 26: 198-205.
101. Villablanca AC. Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro. J Appl Physiol 1998; 84: 2089-2098.
102. Zhang S, Day I, Ye S. Nicotine induced changes in gene expression by human coronary artery endothelial cells. Atherosclerosis 2001; 154: 277-283.
103. Carty CS, Soloway PD, Kayastha S et al. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J Vasc Surg 1996; 24: 927-934.
104. Cucina A, Sapienza P, Corvino V, et al. Nicotine induces platelet-derived growth factor release and cytoskeletal alteration in aortic smooth muscle cells. Surgery 2000; 127: 72-78.
105. Lee WO, Wright SM. Production of endothelin by cultured human endothelial cells following exposure to nicotine or caffeine. Metabolism 1999; 48: 845-848.
106. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
107. Heeschen C, Chang E, Aicher A, Cooke JP. Endothelial progenitor cells participate in nicotine-mediated angiogenesis. J Am Coll Cardiol 2006; 48: 2553-2560.
108. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
109. George J, Afek A, Abashidze A, et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005; 25: 2636-2641.
110. Avogaro A, Fadini GP. The Janus face of nicotinic angiogenesis. J Am Coll Cardiol 2006; 48: 2561-2563.
111. Kornowski, R., Fuchs, S., Epstein, S.E., Leon, M.B.: US20067097832 ( 2006).
112. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-684.
113. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001; 7: 345-350.
114. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
115. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Ceti Biol 1996; 16: 4604-4613.
116. Guo D, Jia Q, Song HY, Warren RS, Donner DB. Vascular endothelial cell growth factor promotes tyrosme phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 1995; 270: 6729-6733.
117. Breier G, Clauss M, Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 1995; 204: 228-239.
118. Voskuil M, van Royen N, Hoefer IE, et al. Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. Am J Physiol Heart Circ Physiol 2003; 284: H1422-H1428.
119. Donahue RE, Seehra J, Metzger M, et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1998; 241: 1820-1823.
120. Peters WP, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte ecolony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
121. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. The Lancet 367: 113-121.
122. Hebbel, R.P., Lin, Y., Lollar, J.S.: US20056852537 (2005).
123. Hladovec J. Circulating endothelial cells as a sign of vessel wall lesions. Physiol Bohemoslov 1978; 27: 140-144.
124. Hladovec J, Prerovsky I, Stanek V, Fabian J. Circulating endothelial cells in acute myocardial infarction and angina pectoris. Klin Wochenschr l978; 56: 1033-1036.
125. Weber G, Losi M, Toti P, Vatti R. Circulating endothelial-like cells in arterial peripheral blood of hypercholesterolemic rabbits. Artery 1979; 5: 29-36.
126. Goon P& Lip GY, Boos CJ, Stonelake PS, Blann AD. Circulating endothelial cells, endothelial progenitor cells, and endothelial. microparticles in cancer. Neoplasia 2006; 8: 79-88.
127. Khan SS, Solomon MA, McCoy JP, Jr. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 2005; 64: 1-8.
128. Boos CJ, Jaumdally RJ, MacFadyen RJ, Varma C, Lip GY. Circulating endothelial cells and von Willebrand factor as indices of endothelial damage/dysfunction in coronary artery disease: a comparison of central vs. peripheral levels and effect of coronary angioplasty. J Thromb Haemost 2007; 5: 630-632.
129. Goon PK, Boos CJ, Lip GY. Circulating endothelial cells: markers of vascular dysfunction. Clin Lab 2005; 51: 531-538.
130. Friedman HM. Infection of endothelial cells by common human viruses. Rev Infect Dis 1989; 11 Suppl 4: S700-S704.
131. Furcht, L.T., Verfaillie, C.M., Reyes, M.: US20067015037 (2006).
132. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
133. Gearhart JD, Mintz B. Contact-mediated myogenesis and increased acetylcholinesterase activity in primary cultures of mouse teratocarcinoma cells. Proc Natl Acad Sci USA 1974; 71: 1734-1738.
134. Jakob H, Boon T, Gaillard J, Nicolas J, Jacob F. Teratocarcinoma of the mouse: isolation, culture and properties of pluripotential cells. Ann Microbiol (Paris) 1973; 124: 269-282.
135. Kahan BW, Ephrussi B. Developmental potentialities of clonal in vitro cultures of mouse testicular teratoma. J Natl Cancer Inst 1970; 44: 1015-1036.
136. Axelrod HR. Embryonic stem cell lines derived from blastocysts by a simplified technique. Dev Biol 1984; 101: 225-228.
137. Evans MI, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 292: 154-156.
138. Wobus AM, Boheler KR. Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev 2005; 85: 635-678.
139. Skottman H, Hovatta O. Culture conditions for human embryonic stem cells. Reproduction 2006; 132: 691-698.
140. Xu C, Inokuma MS, Denham J, et al. Feeder-free growth of undffferentiated human embryonic stem cells. Nat Biotechnol 2001; 19: 971-974.
141. Xu C, Jiang J, Sottile V, et al. Immortalized fibroblast-like cells derived from human embryonic stem cells support undifferentiated cell growth. Stem Cells 2004; 22: 972-980.
142. Amit M, Shariki C, Margulets V, Itskovitz-Eldor J. Feeder layer- and serum-free culture of human embryonic stem cells. Biol Reprod 2004; 10: 837-845.
143. Stojkovic P, Lako M, Stewart, R, et al. An autogeneic feeder cell system that efficiently supports growth of undifferentiated human embryonic stem cells. Stem Cells 2005; 23: 306-314.
144. Klimanskaya I, Chung Y, Meisner L, et al. Human embryonic stem cells derived without feeder cells. Lancet 2005; 365: 1636-1641.
145. Ludwig TE, Levenstein ME, Jones JK et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006; 24: 185-187.
146. Kehat I, Kenyagin-Karsenti D, Snir M, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001; 108: 407-414.
147. Eriksson, P., Karin, E., Tallheden, T., Enerback, S.: US20070010010A1 (2007).
148. Sjogren-Jansson E, Zetterstrom K Moya K, et al. Large-scale propagation of four undifferentiated human embryonic stem cell lines in a feeder-free culture system. Dev Dyn 2005; 233: 1304-1314.
149. Li, R.A. Akar, F.G,. Cho, H., Marban, E., Tomaselli, G.: W006017567A2 (2006).
150. Rosen MR, Brink PR, Cohen IS, Robinson RB. Genes, stem cells and biological pacemakers. Cardiovasc Res 2004; 64: 12-23.
151. Edelberg JM, Aird WC, Rosenberg RD. Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. J Clin Invest 1998; 101: 337-343.
152. Edelberg JM, Huang DT, Josephson ME, Rosenberg RD. Molecular enhancement of porcine cardiac chronotropy. Heart 2001; 86: 559-562.
153. Borlak J, Thum T. Hallmarks of ion channel gene expression in end-stage heart failure. FASEB J 2003; 17: 1592-1608.
154. Mummery C, Ward D, van den Brink CE, et al. Cardiomyocyte differentiation of mouse and human embryonic stem cells. J Anat 2002; 200: 233-242.
155. Giacomello, A., Messina, E., Battaglia, M., Frati, G.: US2007020758A1 (2007).
156. Passier R, Mummery C. Cardiomyocyte differentiation from embryonic and adult stem cells. Curr Opin Biotechnol 2005; 16: 498-502.
157. Hierlihy AM, Scale P, Lobe CG, Rudnicki MA, Megeney LA. The post-natal heart contains a myocardial stem cell population. FEBS Lett 2002; 530: 239-243.
158. Lints TJ, Parsons LK Hartley L, Lyons I, Harvey RP. Nkx-2.5: a novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants. Development 1993; 119: 969.
159. Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 1997; 276: 1404-1407.
160. Watt AJ, Battle MA, Li J, Duncan SA. GATA4 is essential for formation of the proepicardium and regulates cardiogenesis. Proc Natl Acad Sci USA 2004; 101: 12573-12578.
161. Messina E, De Angelis L, Frati G, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 2004; 95: 911-921.
162. Barile L, Messina E, Giacomello A, Marban E. Endogenous cardiac stem cells. Prog Cardiovasc Dis 2007; 50: 31-48.